Titlebook: Cardio-Oncology; Management of Toxici Antonio Russo,Nicola Maurea,Antonio Giordano Book 2022 The Editor(s) (if applicable) and The Author(s

明顯

書目名稱Cardio-Oncology影響因子(影響力)




書目名稱Cardio-Oncology影響因子(影響力)學(xué)科排名




書目名稱Cardio-Oncology網(wǎng)絡(luò)公開度




書目名稱Cardio-Oncology網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Cardio-Oncology被引頻次




書目名稱Cardio-Oncology被引頻次學(xué)科排名




書目名稱Cardio-Oncology年度引用




書目名稱Cardio-Oncology年度引用學(xué)科排名




書目名稱Cardio-Oncology讀者反饋




書目名稱Cardio-Oncology讀者反饋學(xué)科排名

chuckle

Collar

陰險(xiǎn)

Management of Patients with Cardiac Toxicity: The Point of View of the Oncologist,iological toxicities. Different types of cardiotoxicity can also occur with cell-based immune-therapy treatments (e.g., CAR-T), requiring specific diagnosis and management protocols. Because of the high morbidity and mortality, an early diagnosis of cardiological irAEs is essential for framing the o

phlegm

CHIDE

CHIDE

Outshine

祖?zhèn)?/a>

Atemwegssicherung, Intubation und Beatmung,ligand-1 (PD-L1) checkpoint inhibitors have a crucial role in oncological treatments, resulting in an improvement of progression-free survival (PFS) and overall survival (OS) compared with standard treatments. Moreover, different safety analyses established that immunotherapy is well-tolerated with

結(jié)構(gòu)

,St?rungen der Vitalfunktionen,scular system. The most clinically relevant cardiovascular adverse event is myocarditis, with an incidence rate ranging from 0.27% of patients treated with single-agent ICIs up to 2.4% of patients treated with combinations. Immune-related myocarditis is burdened by high mortality, with a fatality ra